Biocon share news, announcements and annual reports
NSE: BIOCONBSE: 532523Pharmaceuticals & BiotechnologyMid Cap
Biocon Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2004
Last close ₹351.80down ₹0.10 (0.03%)BSE ₹352.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹351.90.
30 Oct: open ₹352.70, high ₹355.50, low ₹348.70
52-week range of traded prices to 30 Oct 2026
₹318.40Low, 23 Oct 2026₹447.15High, 16 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹57,333 Cr173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 115.75
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 64.09
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.14%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,63,63747.1% delivered
Biocon disputes and clarifications
14 filed, newest first.
Sep 2025
Mar 2025
Nov 2019
7 Nov · Legal
Exchange has sought clarification from Biocon Limited with respect to announcement dated 23-Oct-2019, regarding change in Director(s) of the company. On basis of above the Company is required to clarify following: 1. Confirmation from resigning independent director that there is no other material reasons other than provided. The response of the Company is awaited.
May 2017
Jan 2017
25 Jan · Legal
Exchange has sought clarification from Biocon Limited with respect to announcement dated 25-Jan-2017, informing that based on the recommendation by the Nomination and Remuneration Committee, Mr. Rajiv Balakrishnan was appointed as the Company Secretary and Compliance Officer of the Company by the Board of Directors at their meeting held on January 24, 2017.On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);The response of the Company is awaited.
Apr 2016
Aug 2015
Jan 2015
12 Jan · Legal
Exchange had sought clarification from Biocon Limited with respect to an announcement dated January 12, 2015, wherein the Company informed the Exchange that M/s Silver Leaf Oak (Mauritius) Limited has assigned its rights and obligations for acquisition of 10% stake in Syngene International Limited ('Syngene') to M/s IVF Trustee Company Private limited ('IVF'), a fund advised by India Value Fund Advisors. Biocon Research limited, a wholly owned subsidiary of the Company has concluded such sale to IVF. Post conclusion of the above, Biocon and BRL jointly hold 85.54% stake in Syngene. The Company has clarified as follows: a) The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year; Company Response: Syngene International Limited is a subsidiary of the Company and the details of the turnover, income and networth are disclosed in the Statement under Section 212 of the Companies Act, 1956. The same formed part of our Annual Report (Page 156). The statement is attached herewith for your ready reference. b) Date on which the agreement for sale has been entered into; Company Response: The Agreement was entered into on September 18, 2014 (at which time the intimation to the exchange was made). On January 9, 2015, Silver Leaf Oak (Mauritius) Limited assigned its interest in the contract to IVF Trustee Company Private Limited. Post the said assignment, the consideration was received on January 12, 2015 by Biocon Research Limited, which has been intimation to the Exchange today. c) Consideration received from such sale/disposal; Company Response:The consideration was mentioned by us in the earlier communication to the Stock Exchange. Biocon Research Limited transferred 10% stake in Syngene at an enterprise valuation of Rs 3,800 Crores (the consideration thereby being Rs 380 Crores for the 10% stake) d) Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm s length; Company Response: The transaction has been made with an independent part (ie. IVF Trustee Company Private Limited).12 Jan · Legal
Exchange has sought clarification from Biocon Limited with respect to an announcement dated January 12, 2015, regarding press Release dated September 18, 2014, Company informed the Exchange that M/s Silver Leaf Oak (Mauritius) Limited has assigned its rights and obligations for acquisition of 10% stake in Syngene International Limited ('Syngene') to M/s IVF Trustee Company Private limited ('IVF'), a fund advised by India Value Fund Advisors. Biocon Research limited, a wholly owned subsidiary of the Company has concluded such sale to IVF. Post conclusion of the above, Biocon and BRL jointly hold 85.54% stake in Syngene . On basis of above Company is required to clarify following: a) The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year; b) Date on which the agreement for sale has been entered into c) Consideration received from such sale/disposal; d) Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm s length. Response from the Company is awaited.
Dec 2014
15 Dec · Legal
Exchange has sought clarification from Biocon Limited with respect to recent news item captioned Biocon Plans to Set up Mfg Unit in Vizag. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: "a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement". The response from the Company is awaited.
Apr 2008
15 Apr · Legal
Clarification to the article that has appeared on the Cover Page of 'Mint' on April 14, 2008 with the headline 'Biocon to buy US firm for $400 mn', that: "Biocon Limited would like to clarify that this article is speculative and deny the Headline and the related information contained in the article. While it is true that the company had earlier indicated an intent to acquire marketing companies abroad, no acquisition target has been identified and the information contained in the article is unsubstantiated. There has been no comment form any Biocon spokesperson, as is clearly mentioned in the article: 'A Biocon spokesperson declined to comment as the firm is in the silent period ahead of the announcement of its quarterly results in keeping with the guidelines of stock market regulator Securities and Exchange Board of India (SEBI)'. All announcements by the company will be made as per SEBI guidelines, with prior intimation to the Stock Exchanges".